Physician profile
Suzanne Meeks
NPI 1679746044
$3,934.57
in general payments reported to CMS, 2019-2025
33 companies · $365 in 2025
The $365 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,520 · 2022: $403 · 2023: $925 · 2024: $721 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,887 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,886.80 |
| Education | $124.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $765.72 | 2021-2025 | |
| Novo Nordisk INC | $510.98 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.34 | 2021-2024 | Synjardy, Jardiance, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $340.80 | 2021-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $240.77 | 2021-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Astrazeneca Pharmaceuticals Lp | $240.07 | 2021-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $172.57 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $145.92 | 2021-2024 | |
| Astellas Pharma US INC | $143.67 | 2023-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $139.27 | 2021-2023 | |
| Grifols USA, LLC | $109.77 | 2021-2024 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $105.44 | 2021-2023 | Trintellix |
| Abbott Laboratories | $95.91 | 2021-2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $91.21 | 2021 | |
| Alnylam Pharmaceuticals INC. | $50.70 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $46.75 | 2021 | |
| Glaxosmithkline, LLC. | $45.54 | 2021-2025 | Trelegy Ellipta |
| Antares Pharma, INC. | $38.49 | 2024-2025 | Xyosted |
| Amgen INC. | $36.18 | 2021 | |
| Ibsa Pharma INC. | $35.66 | 2021-2023 | Tirosint, Licart |
| Phathom Pharmaceuticals, INC. | $32.98 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $25.52 | 2021 | |
| Halozyme INC | $20.73 | 2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.25 | 2022 | |
| Eisai INC. | $16.80 | 2022 | |
| Bausch Health US, LLC | $16.33 | 2022 | |
| Currax Pharmaceuticals LLC | $16.30 | 2025 | Contrave |
| Dexcom, INC. | $15.71 | 2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $15.67 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.52 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.36 | 2023 | Quviviq |
| Sanofi Pasteur INC. | $13.09 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Meeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.